Kura Oncology (KURA) Cash from Operations (2010 - 2026)
Kura Oncology (KURA) posted quarterly Cash from Operations of 85854000.0 for Q1 2026, down 19.36% year-over-year from 106469321.69 in Q1 2025, and down 173.21% quarter-over-quarter from 117273000.0 in Q4 2025.
Kura Oncology (KURA) Cash from Operations (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Cash from Operations for 17 consecutive years, with 85854000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 19.36% year-over-year to 85854000.0; the TTM figure through Mar 2026 stood at 77985000.0 (down 170.11% YoY), while the FY2025 annual figure was 64058000.0, down 147.69% from the prior year.
- Cash from Operations slipped to 85854000.0 in Q1 2026 per KURA's latest filing, from 117273000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 269131000.0 in Q4 2024 and bottomed at 85854000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 14734176.47 across 5 years, with a median of 32181000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 884.46% — and 2025, when it tumbled 85.61%.
- Kura Oncology's Cash from Operations stood at 26530000.0 in 2022, then slipped by 29.32% to 34308000.0 in 2023, then surged by 884.46% to 269131000.0 in 2024, then sank by 56.43% to 117273000.0 in 2025, then sank by 173.21% to 85854000.0 in 2026.
- Business Quant data shows KURA's Cash from Operations at 85854000.0 in Q1 2026, 117273000.0 in Q4 2025, and 80627000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -62.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.55 Mn |
| Jun 30, 2026 | -62.55 Mn |
| Mar 31, 2026 | -85.85 Mn |
| Mar 31, 2026 | -85.85 Mn |
| Dec 31, 2025 | 117.27 Mn |
| Dec 31, 2025 | 117.27 Mn |
| Sep 30, 2025 | -80.63 Mn |
| Sep 30, 2025 | -80.63 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Mar 31, 2025 | -71.93 Mn |
| Mar 31, 2025 | -71.93 Mn |
| Dec 31, 2024 | 269.13 Mn |
| Dec 31, 2024 | 269.13 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Jun 30, 2024 | -42.53 Mn |
| Jun 30, 2024 | -42.53 Mn |
| Mar 31, 2024 | -48.84 Mn |
| Mar 31, 2024 | -48.84 Mn |